IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) reached a new 52-week low during trading on Friday . The company traded as low as $194.97 and last traded at $195.24, with a volume of 575499 shares traded. The stock had previously closed at $202.94.
Wall Street Analyst Weigh In
IQV has been the subject of several research analyst reports. TD Cowen cut their price objective on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Evercore ISI cut their price target on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. BTIG Research reduced their target price on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Finally, Robert W. Baird decreased their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $259.13.
Read Our Latest Stock Report on IQVIA
IQVIA Price Performance
The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a 50 day moving average of $227.96 and a 200-day moving average of $228.59. The firm has a market capitalization of $34.96 billion, a P/E ratio of 25.62, a P/E/G ratio of 2.17 and a beta of 1.51.
Insiders Place Their Bets
In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 6.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.60% of the company's stock.
Institutional Trading of IQVIA
Large investors have recently bought and sold shares of the business. Empowered Funds LLC grew its holdings in shares of IQVIA by 35.5% during the first quarter. Empowered Funds LLC now owns 2,512 shares of the medical research company's stock worth $635,000 after purchasing an additional 658 shares during the last quarter. Sei Investments Co. increased its position in shares of IQVIA by 4.8% during the first quarter. Sei Investments Co. now owns 57,887 shares of the medical research company's stock worth $14,638,000 after buying an additional 2,638 shares during the period. HBK Sorce Advisory LLC boosted its position in IQVIA by 10.9% during the first quarter. HBK Sorce Advisory LLC now owns 989 shares of the medical research company's stock valued at $250,000 after acquiring an additional 97 shares during the last quarter. Great Lakes Retirement Inc. grew its holdings in IQVIA by 3.6% during the 1st quarter. Great Lakes Retirement Inc. now owns 2,393 shares of the medical research company's stock worth $605,000 after acquiring an additional 84 shares during the period. Finally, Banco Santander S.A. bought a new stake in IQVIA in the first quarter worth approximately $419,000. 89.62% of the stock is owned by institutional investors and hedge funds.
About IQVIA
(
Get Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
